Categories: Market Research

Proteasome Inhibitors Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Proteasome Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Proteasome Inhibitors Market:

https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

According to The Business Research Company’s Proteasome Inhibitors Global Market Report 2024, The proteasome inhibitors market size has grown strongly in recent years. It will grow from $1.86 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to scientific breakthroughs, clinical research and trials, fda approvals, rising cancer cases, advancements in drug delivery.

The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to precision medicine approaches, next-generation inhibitors, healthcare infrastructure growth, targeted therapies combination, emerging markets adoption. Major trends in the forecast period include immunotherapy combinations, selective proteasome inhibition, longer half-life inhibitors, oral formulations, resistant cancer variant treatments.

The increasing prevalence of pancreatic cancer is expected to propel the growth of the proteasome inhibitors market going forward. Pancreatic cancer is a type of cancer that develops in the cells of the pancreas, an organ located in the abdomen behind the stomach. Proteasome inhibitors are primarily used to treat pancreatic cancer, where proteasome plays a critical role in promoting cell survival and growth by degrading proteins that regulate cell cycle progression and cell death. It disrupts cancer cell survival and inhibits tumor growth and metastasis. For instance, in March 2023, according to the reports by the American Society of Clinical Oncology (ASCO), a US-based professional organization for oncology professionals, an estimated 64,050 adults in the US were diagnosed with pancreatic cancer by 2023, and 50,550 people died of pancreatic cancer. Furthermore, globally, 495,773 people were diagnosed, and 466,003 died of pancreatic cancer in 2020. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the proteasome inhibitors market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12251&type=smp

The proteasome inhibitors market covered in this report is segmented –

1) By Product: Velcade, Kyprolis, Ninlaro, Other Products

2) By Drugs: Bortezomib, Carfilzomib, Ixazomib

3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospital, Specialty Clinics, Other End-Users

Increases in investments are a key trend gaining popularity in the proteasome inhibitors market. Major companies operating in the proteasome inhibitors market are investing in developing and commercializing proteasome inhibitors, which can play a significant role in advancing research and bringing new treatments to the market. For instance, in September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of new-class proteasome inhibitors, received $10.96 million (EUR 10 million) of investments from SV Investment, a South Korea-based venture capital firm, and KHAN Technology Transfer Fund I, a Germany-based venture capital firm, as well as Atinum Investment Co., Ltd. and Daol Investment & Securities Co., Ltd., South Korea-based venture capital firms. This investment aims to develop novel proteasome inhibitors for treating cancer and inflammatory and autoimmune disorders. With the help of this funding, QLi5’s pipeline of very distinct proteasome inhibitors will be advanced to the beginning of clinical studies addressing multiple indications.

The proteasome inhibitors market report table of contents includes: